Parecoxib sodium

Research use only, not for human use.

A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.

A potent and selective COX-2 inhibitor; a water-soluble prodrug of valdecoxib.Pain Approved.

Parecoxib Sodium (0-200?μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells.Parecoxib Sodium (200?μM; 24-48 hours) results in a decreased migratory ability of U343 cells than PBS-treated group. :Cell Viability Assay Cell Line:GBM cells:U251 and U343 cells Concentration:0 μM, 20 μM, 50 μM, 100 μM and 200?μM Incubation Time:24-48 hoursResult:Resulted in a slower BrdU incorporation rate of GBM cells including U251 and U343 cells.

Parecoxib Sodium (intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10?mg/kg shows higher levels of percentage of time spent in the open arms. Animal Model:Naive adult male ICR mice, 15?weeks old and weighing 25-35?g Dosage:2.5?mg/kg, 5.0 ?mg/kg or 10?mg/kg Administration:Intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days Result:Exerted an anxiolytic-like effect in the elevated plus-maze test.

SC-69124A

Chromatin/Epigenetic

COX

COX

Neurological Disease

Pain

198470-85-8

392.4041

C19H17N2NaO4S

>98% (HPLC)

DMSO：≥ 32 mg/mL

CCC(=O)[N-]S(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C.[Na+]

Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-, sodium salt (1:1)

(-20℃)

With Ice Pack

≥ 2 years